We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAMYT
RNS Number : 8035Y
Amryt Pharma PLC
08 March 2017
AIM: AMYT, ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Date of Results
Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that results for the financial year to 31 December 2016 are expected to be reported on Thursday, 30 March 2017.
Enquiries:
c/o KTZ Communications Amryt Pharma plc +44 (0)20 3178 6378 Joe Wiley, CEO Rory Nealon, CFO/COO Shore Capital +44 (0) 20 7408 4090 Nomad and Joint Broker Bidhi Bhoma, Edward Mansfield Davy +353 (1) 679 6363 ESM Adviser and Joint Broker John Frain, Anthony Farrell Stifel +44 (0) 20 7710 7600 Joint Broker Jonathan Senior, Ben Maddison KTZ Communications +44 (0) 20 3178 6378 Katie Tzouliadis, Emma Pearson
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
The Company recently acquired an exclusive licence to sell LOJUXTA (lomitapide), across the EU and other territories including the Middle East, North Africa, Turkey and Israel. LOJUXTA is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.
Amryt's lead development product, AP101 (Episalvan), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to develop AP101 (Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. The Company is currently planning a Phase 3 study of AP101 (Episalvan) in EB, which has been granted US and EU orphan drug designation. The global market opportunity for EB is estimated to be circa EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA.
The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSSEEFWFWSELD
(END) Dow Jones Newswires
March 08, 2017 02:01 ET (07:01 GMT)
1 Year Amryt Pharma Chart |
1 Month Amryt Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions